Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Chugai to Participate in Multinational Study of Avastin in Breast Cancer
December 27, 2011
- Sawai Pharmaceutical Wins Ebastine Patent Dispute
December 26, 2011
- JT to Introduce Anti-HIV Drug Booster from US Company
December 26, 2011
- Toray, JT, Torii Terminate Joint Development of Additional Indication for Nalfurafine
December 26, 2011
- Pfizer Files NDA for Intestinal Amebiasis Treatment Paromomycin in Japan
December 26, 2011
- Novo Nordisk Pharma Submits NDA for Insulin Degludec
December 26, 2011
- Takeda to Set Up New Unit to Support Investigator-Initiated Research
December 22, 2011
- BMKK, Pfizer Japan Apply for Apixaban for SPAF in Japan
December 22, 2011
- Takeda to Acquire Intellikine to Enhance Oncology Pipeline
December 22, 2011
- Ranbaxy Settles with US FDA, Commits to Improvements in GMP Compliance, Data Integrity: Daiichi Sankyo
December 22, 2011
- Daiichi Sankyo Grants Marketing Rights for Cravit to Ranbaxy in Malaysia
December 22, 2011
- Rohto’s Mentholatum Medi-Quick H on Track to Become Hit Product in 1st Year
December 22, 2011
- Nexium Takes No. 1 and No. 2 Position in HP Market: RepTrack Survey
December 21, 2011
- MTPC, Novartis Pharma Focused on Promoting Proper Use of MS Treatment Imusera/Gilenya
December 21, 2011
- Chugai to Establish Pool System of Candidate Leaders
December 20, 2011
- Meiji Seika Pharma Licenses Udenafil from Dong-A Pharmaceutical
December 20, 2011
- GSK Applies for Add’l Indication for Botox for Axillary Hyperhidrosis
December 20, 2011
- SMBC Nikko Securities Includes Astellas Pharma in 20 Stocks to Watch in 2012
December 19, 2011
- Takeda Decides not to Commercialize Peginesatide in Japan
December 19, 2011
- Valeant Announces Successful Results from PIII Onychomycosis Study of Efinaconazole
December 19, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…